Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Receivables (2020 - 2023)

Historic Change in Receivables for Barinthus Biotherapeutics (BRNS) over the last 4 years, with Q3 2023 value amounting to -$194000.0.

  • Barinthus Biotherapeutics' Change in Receivables rose 9821.46% to -$194000.0 in Q3 2023 from the same period last year, while for Jun 2024 it was -$194000.0, marking a year-over-year increase of 9884.53%. This contributed to the annual value of -$5.8 million for FY2023, which is 19943.43% down from last year.
  • Per Barinthus Biotherapeutics' latest filing, its Change in Receivables stood at -$194000.0 for Q3 2023, which was up 9821.46% from -$645000.0 recorded in Q2 2023.
  • In the past 5 years, Barinthus Biotherapeutics' Change in Receivables registered a high of $18.4 million during Q1 2022, and its lowest value of -$10.9 million during Q3 2022.
  • Its 4-year average for Change in Receivables is -$67000.0, with a median of -$284000.0 in 2021.
  • The largest annual percentage gain for Barinthus Biotherapeutics' Change in Receivables in the last 5 years was 892307.69% (2022), contrasted with its biggest fall of 18120000.0% (2022).
  • Quarter analysis of 4 years shows Barinthus Biotherapeutics' Change in Receivables stood at $448000.0 in 2020, then plummeted by 116.29% to -$73000.0 in 2021, then tumbled by 350.68% to -$329000.0 in 2022, then skyrocketed by 41.03% to -$194000.0 in 2023.
  • Its last three reported values are -$194000.0 in Q3 2023, -$645000.0 for Q2 2023, and -$5.0 million during Q1 2023.